×

Pfizer licenses CAR-T therapies from China’s Starna in up to $2.6 billion deal

By Thomson Reuters Nov 18, 2026 | 6:54 AM

Nov 18 (Reuters) – Pfizer said on Wednesday it had struck an exclusive licensing agreement with China’s Starna Therapeutics to ​develop three CAR-T therapies for autoimmune ‌diseases, in a deal worth up to $2.6 billion.

The deal marks another bet on a Chinese biotech by the pharma major as it seeks to reignite ‌growth ​by 2028 while preparing for ⁠a wave of ⁠patent expirations and continued declines in COVID-related revenue.

• Pfizer will pay Starna $330 million upfront and could pay up to $2.3 billion more ​if the treatments meet development, regulatory and sales milestones. The therapies have not ⁠yet entered human trials

• ⁠Starna would also receive royalties on ​sales of any approved products

• The agreement gives ​Pfizer rights to develop and commercialize ‌three early-stage autoimmune disease programs outside Greater China, with initial clinical trial supplies to be manufactured at its US facilities

• In vivo ⁠CAR-T therapies are designed to genetically reprogram immune cells directly inside the body, allowing them to ⁠target and ‌eliminate disease-causing immune cells

• By ⁠contrast, conventional CAR-T treatments involve the ​complex ‌process of collecting and re-engineering ​a patient’s ⁠cells outside the body before reinfusing them

• The deal follows Pfizer’s $10.5 billion agreement with Innovent Biologics in May and an earlier deal with China’s 3SBio in 2025

(Reporting by Padmanabhan Ananthan ​in Bengaluru)